These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

484 related items for PubMed ID: 15646065

  • 1. Resistance and replicative capacity of HIV-1 strains selected in vivo by long-term enfuvirtide treatment.
    Menzo S, Castagna A, Monachetti A, Hasson H, Danise A, Carini E, Bagnarelli P, Lazzarin A, Clementi M.
    New Microbiol; 2004 Apr; 27(2 Suppl 1):51-61. PubMed ID: 15646065
    [Abstract] [Full Text] [Related]

  • 2. Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment.
    Menzo S, Castagna A, Monachetti A, Hasson H, Danise A, Carini E, Bagnarelli P, Lazzarin A, Clementi M.
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3253-9. PubMed ID: 15328081
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Resistance to enfuvirtide, the first HIV fusion inhibitor.
    Greenberg ML, Cammack N.
    J Antimicrob Chemother; 2004 Aug; 54(2):333-40. PubMed ID: 15231762
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Virological fitness of HIV in patients with resistance to enfuvirtide.
    Chibo D, Roth N, Roulet V, Skrabal K, Gooey M, Carolan L, Nicholls J, Papadakis A, Birch C.
    AIDS; 2007 Sep 12; 21(14):1974-7. PubMed ID: 17721108
    [Abstract] [Full Text] [Related]

  • 8. Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen.
    Deeks SG, Lu J, Hoh R, Neilands TB, Beatty G, Huang W, Liegler T, Hunt P, Martin JN, Kuritzkes DR.
    J Infect Dis; 2007 Feb 01; 195(3):387-91. PubMed ID: 17205477
    [Abstract] [Full Text] [Related]

  • 9. Long-term monitoring of genotypic and phenotypic resistance to T20 in treated patients infected with HIV-1.
    Pérez-Alvarez L, Carmona R, Ocampo A, Asorey A, Miralles C, Pérez de Castro S, Pinilla M, Contreras G, Taboada JA, Nájera R.
    J Med Virol; 2006 Feb 01; 78(2):141-7. PubMed ID: 16372284
    [Abstract] [Full Text] [Related]

  • 10. Dynamics of enfuvirtide resistance in HIV-infected patients during and after long-term enfuvirtide salvage therapy.
    Poveda E, Rodés B, Lebel-Binay S, Faudon JL, Jimenez V, Soriano V.
    J Clin Virol; 2005 Dec 01; 34(4):295-301. PubMed ID: 16286053
    [Abstract] [Full Text] [Related]

  • 11. Dynamics of drug-resistant HIV-1 in plasma and peripheral blood cells in patients during and after enfuvirtide therapy.
    Poveda E, Briz V, Paraskevis D, Barreiro P, Hatzakis A, Soriano V.
    AIDS Res Hum Retroviruses; 2007 Sep 01; 23(9):1078-82. PubMed ID: 17919101
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Performance of human immunodeficiency virus type 1 gp41 assays for detecting enfuvirtide (T-20) resistance mutations.
    Marcial M, Lu J, Deeks SG, Ziermann R, Kuritzkes DR.
    J Clin Microbiol; 2006 Sep 01; 44(9):3384-7. PubMed ID: 16954280
    [Abstract] [Full Text] [Related]

  • 17. Dynamics of enfuvirtide resistance mutations in enfuvirtide-experienced patients remaining in virological failure under salvage therapy.
    Charpentier C, Jenabian MA, Piketty C, Karmochkine M, Tisserand P, Laureillard D, Bélec L, Si-Mohamed A, Weiss L.
    Scand J Infect Dis; 2011 May 01; 43(5):373-9. PubMed ID: 21341978
    [Abstract] [Full Text] [Related]

  • 18. Evolution of genotypic resistance to enfuvirtide in HIV-1 isolates from different group M subtypes.
    Covens K, Kabeya K, Schrooten Y, Dekeersmaeker N, Van Wijngaerden E, Vandamme AM, De Wit S, Van Laethem K.
    J Clin Virol; 2009 Apr 01; 44(4):325-8. PubMed ID: 19237313
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen.
    Lalezari JP, Bellos NC, Sathasivam K, Richmond GJ, Cohen CJ, Myers RA, Henry DH, Raskino C, Melby T, Murchison H, Zhang Y, Spence R, Greenberg ML, Demasi RA, Miralles GD, T1249-102 Study Group.
    J Infect Dis; 2005 Apr 01; 191(7):1155-63. PubMed ID: 15747252
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.